person · Reporting owner
Ferguson James J. III
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cadrenal Therapeutics, Inc.CVKD · Entity 8251 | Chief Medical Officer | February 05, 2025 | February 06, 2025 |
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | Chief Medical Officer | December 15, 2023 | December 16, 2023 |
| Mineralys Therapeutics, Inc.MLYS · Entity 4432 | Chief Medical Officer | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cadrenal Therapeutics, Inc.
Report date February 05, 2025 · Filed February 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $19.75 · Expires 2035-02-04 | Direct | 60,000 |
Reported balance
After 2025-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-05 · Grant · Acquired 60,000 · Balance 60,000 F1: Consists of options to purchase 60,000 shares of common stock, which shall vest 1/4 on March 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of options to purchase 60,000 shares of common stock, which shall vest 1/4 on March 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant.
Matinas BioPharma Holdings, Inc.
Report date December 15, 2023 · Filed December 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2033-12-15 | Direct | 1,200,000 |
Reported balance
After 2023-12-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-15 · Grant · Acquired 1,200,000 · Balance 1,200,000 F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024.
Mineralys Therapeutics, Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,400 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 102,400 · Balance 102,400 F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $27.38 · Expires 2036-08-10 | Direct | 135,000 |
Reported balance
After 2026-08-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-10 · Grant · Acquired 135,000 · Balance 135,000 F2: The stock option vests as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.
F2: The stock option vests as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 23:33 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 135,000 | $0.00 Strike: $27.38 | $0.00 |
DisclosureSEC source: 0001933414-26-000120 · wk-form4_1786577597.xml · derivative · entry 2 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2036-08-10 F2 · derivative.exercise_date: The stock option vests as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 23:33 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantCommon Stock | 102,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001933414-26-000120 · wk-form4_1786577597.xml · nonDerivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,400 F1 · shares: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 21:51 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 60,000 | $0.00 Strike: $19.75 | $0.00 |
DisclosureSEC source: 0001213900-25-010973 · ownership.xml · derivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-02-04 F1 · security: Consists of options to purchase 60,000 shares of common stock, which shall vest 1/4 on March 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant. Read SEC document |
| December 15, 2023 Filed Dec 16, 2023 02:46 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock Option (right to Buy) · Derivative | 1,200,000 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001493152-23-045168 · ownership.xml · derivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Common Stock · 1,200,000 shares Expires 2033-12-15 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 16:17 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock Option (right to Buy) · Derivative | 625,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001493152-22-036232 · ownership.xml · derivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,000 Underlying: Common Stock · 625,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 02:18 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock Option (right to Buy) · Derivative | 587,600 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0000905718-21-001605 · matinas_fm4dec142021.xml · derivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,600 Underlying: Common Stock · 587,600 shares Expires 2031-12-13 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 23:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 575,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001493152-21-000130 · ownership.xml · derivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 575,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-011532 · ownership.xml · derivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. Vesting is performance based and tied to achievement of positive topline ENHANCE-IT data (the "Milestone"). The option vests as to 1/3 upon achievement of the Milestone, with the remaining options to vest 1/3 on the first anniversary of such Milestone and 1/3 on the second anniversary of such Milestone. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:05 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001493152-20-000120 · ownership.xml · derivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2021 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2021. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 21:58 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 350,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000905718-19-000260 · matinas_form4feb252019.xml · derivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2029-02-24 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% of the shares on February 25, 2020 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on March 31, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.